247 related articles for article (PubMed ID: 33886077)
1. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
Adachi Y; Oze I; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Sugino K; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Takatsuka D; Iwata H
Breast Cancer; 2021 Sep; 28(5):1087-1095. PubMed ID: 33886077
[TBL] [Abstract][Full Text] [Related]
2. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
[TBL] [Abstract][Full Text] [Related]
7. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
8. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
11. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H; Yamamoto Y; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Ohtani S; Kashiwaba M; Taira N; Toyama T; Fujisawa T; Masuda N; Shibahara Y; Sasano H; Yamaguchi T
Breast Cancer Res Treat; 2023 Jun; 199(2):231-241. PubMed ID: 36947277
[TBL] [Abstract][Full Text] [Related]
13. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
14. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
[TBL] [Abstract][Full Text] [Related]
15. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
16. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F; Ceppi M; Lambertini M; Bruzzi P; Ugolini D; Bighin C; Levaggi A; Giraudi S; D'Alonzo A; Vaglica M; Blondeaux E; Sertoli MR; Pronzato P; Del Mastro L
Breast; 2017 Jun; 33():104-108. PubMed ID: 28360014
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
19. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
[No Abstract] [Full Text] [Related]
20. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]